See the DrugPatentWatch profile for Delstrigo
Delstrigo is a brand name for a fixed-dose combination antiretroviral medication used to treat HIV-1 infection. It contains three active ingredients:
* Dolutegravir: An integrase strand transfer inhibitor (INSTI) [1].
* Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI) [1].
* Tenofovir Disoproxil Fumarate (TDF): A nucleotide analog reverse transcriptase inhibitor (NtRTI) [1].
This combination works by preventing the human immunodeficiency virus from replicating [1].
What is Delstrigo approved for?
Delstrigo is approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 30 kg [1]. It is indicated as a complete regimen for individuals who have no known resistance to any of the three components [1].
How does Delstrigo work?
Delstrigo combines three antiretroviral drugs that target HIV at different stages of its lifecycle. Dolutegravir blocks the integration of viral DNA into the human cell's DNA, lamivudine and tenofovir disoproxil fumarate inhibit the reverse transcriptase enzyme, which HIV uses to convert its RNA into DNA [1]. By combining these mechanisms, Delstrigo effectively reduces the amount of HIV in the body [1].
What is the difference between Delstrigo and other HIV medications?
Delstrigo is a single-tablet regimen, meaning it contains all three necessary active ingredients in one pill, taken once daily [1]. This is a common approach for simplifying HIV treatment. Other HIV treatment regimens may involve multiple pills taken at different times of the day, or different combinations of drug classes. The specific composition of Delstrigo—dolutegravir, lamivudine, and tenofovir disoproxil fumarate—differentiates it from other fixed-dose combinations that may contain different antiretrovirals [1].
When does Delstrigo's patent expire?
Information regarding specific patent expiration dates for Delstrigo can be found on specialized patent tracking resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Delstrigo, which can help determine when generic versions may become available [2].
What are the side effects of Delstrigo?
Common side effects reported with Delstrigo include diarrhea, nausea, headache, and nasopharyngitis (common cold symptoms) [1]. More serious potential side effects, though less common, can include hypersensitivity reactions, liver problems, and kidney issues [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
Who manufactures Delstrigo?
Delstrigo is manufactured by ViiV Healthcare [1].
What are the clinical trials for Delstrigo?
The efficacy and safety of Delstrigo are evaluated through clinical trials. Studies have demonstrated that Delstrigo can effectively suppress viral load and maintain it at undetectable levels in patients with HIV-1 [1]. These trials assess viral load reduction, CD4 cell count changes, and the incidence of adverse events [1].
What are the concerns for patients taking Delstrigo?
Patients taking Delstrigo should be aware of potential drug interactions, as dolutegravir can interact with certain other medications [1]. Regular monitoring by a healthcare provider is recommended to assess treatment effectiveness and detect any potential side effects or complications [1]. Patients should also adhere strictly to the prescribed dosage to maintain viral suppression and prevent the development of drug resistance [1].
Sources:
[1] https://www.delstrigo.com/
[2] https://drugpatentwatch.com/